Clinical Trial Update: Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Purinostat Mesylate in relapsed or refractory diffuse large B-cell lymphoma, with the study currently active but not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Purinostat Mesylate (Purinostat Mesylate)

Snippet

Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd | Conditions: Diffuse Large B Cell Lymphoma，DLBCL | Phase 2 | Status: ACTIVE_NOT_RECRUITING